A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

JOURNAL ARTICLE published 1 August 2017 in Clinical Cancer Research

Authors: Myron S. Czuczman | Marek Trněný | Andrew Davies | Simon Rule | Kim M. Linton | Nina Wagner-Johnston | Randy D. Gascoyne | Graham W. Slack | Pierre Brousset | David A. Eberhard | Francisco J. Hernandez-Ilizaliturri | Gilles Salles | Thomas E. Witzig | Pier Luigi Zinzani | George W. Wright | Louis M. Staudt | Yandan Yang | P. Mickey Williams | Chih-Jian Lih | Jacqueline Russo | Anjan Thakurta | Patrick Hagner | Pierre Fustier | Dale Song | Ian D. Lewis